Design Therapeutics (NASDAQ: DSGN) — Company Overview, News & Financial Data
Design Therapeutics develops therapies for genetic diseases, aiming to address root causes through innovative biotechnology.
Design Therapeutics
Design Therapeutics (NASDAQ:DSGN) is a biotechnological firm dedicated to developing treatments for genetic diseases. Focused primarily on addressing the root causes of these diseases, the company leverages its innovative platform to create therapies that target and correct genetic aberrations. Its projects span a variety of conditions, with a particular emphasis on degenerative disorders. By pursuing a blend of cutting-edge science and patient-centric research, Design Therapeutics aims to fulfill its objective of delivering transformative genetic medicines that can vastly improve the lives of patients worldwide.
Snapshot
Operations
Products and/or services of Design Therapeutics
- GeneTAC platform, a proprietary technology for developing medicines to treat genetic disorders by precisely modulating gene expression.
- DT-216 for Friedreich's ataxia, aiming to increase frataxin protein levels for symptomatic relief and disease modification.
- Preclinical programs focused on addressing nucleotide repeat disorders, targeting diseases like myotonic dystrophy.
- Partnerships in gene editing and therapy development, leveraging unique technologies for novel therapeutic products.
- Investment in novel drug delivery systems, enhancing the precision and efficiency of gene-targeted treatments.
- Research on small molecule therapies for addressing genetic mutations and restoring normal gene function.
Design Therapeutics executive team
- Pratik ShahCo-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
- Sean JeffriesChief Operating Officer
- Chris M. StorgardChief Medical Officer
- Aseem Z. AnsariCo-Founder & Scientific Advisor
- Julie D. BurgessChief Accounting Officer
- Doane ChilcoatChief Technology Officer
- Mustapha ParekhGeneral Counsel
- Tadimeti S. RaoChief Scientific Officer
- Jim KerrChief of Manufacturing & Product Development
- Chengzhi ZhangChief Chemist
Latest news about Design Therapeutics
Key financials
Reported results for Design Therapeutics, in USD.
- Market cap
- 647.1M
- Revenue (TTM)
- 33K
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.2
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -79.5M | -69.8M | |
| 0 | -62.4M | -49.6M | |
| 0 | -78.2M | -66.9M | |
| 0 | -67.6M | -58.6M |